Difference between revisions of "Timeline of malaria vaccine"
From Timelines
(→Full timeline) |
|||
| Line 12: | Line 12: | ||
! Year/period !! Type of event !! Event !!Location | ! Year/period !! Type of event !! Event !!Location | ||
|- | |- | ||
| − | | 1987 || || "The RTS,S malaria vaccine candidate is the most advanced in development globally. It was created in 1987 by scientists working at GlaxoSmithKline’s (GSK) laboratories."<ref name="Fact s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> || | + | | 1984 || || "GSK/WRAIR initiate collaboration"<ref name="Fact s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> || |
| + | |- | ||
| + | | 1987 || || "RTS,S is first created by combining the malaria CS protein and hepatitis B surface antigen"<ref name="Fact s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> | ||
| + | "The RTS,S malaria vaccine candidate is the most advanced in development globally. It was created in 1987 by scientists working at GlaxoSmithKline’s (GSK) laboratories."<ref name="Fact s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> || | ||
| + | |- | ||
| + | | 1995 || || "First RTS,S clinical tests in humans begins in adults in US"<ref name="Fact s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> | ||
| + | |- | ||
| + | | 1997 || || Key proof-of-concept (PoC) study shows 6 of 7 volunteers in challenge trial are 100% protected.<ref name="Fact s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> || | ||
|- | |- | ||
| 2009 || Trial || "GlaxoSmithKline Biologicals' (GSKBio) RTS,S" "A Phase III trial of the world’s most clinically advanced malaria vaccine candidate was launched in Kisumu, Kenya, in July 2009, under the auspices of the Kenya Medical Research Institute (KEMRI)/CDC Research and Public Health Collaboration."<ref>{{cite web|title=Malaria Vaccine|url=https://www.cdc.gov/malaria/features/vaccines.html|website=cdc.gov|accessdate=17 April 2017}}</ref> || | | 2009 || Trial || "GlaxoSmithKline Biologicals' (GSKBio) RTS,S" "A Phase III trial of the world’s most clinically advanced malaria vaccine candidate was launched in Kisumu, Kenya, in July 2009, under the auspices of the Kenya Medical Research Institute (KEMRI)/CDC Research and Public Health Collaboration."<ref>{{cite web|title=Malaria Vaccine|url=https://www.cdc.gov/malaria/features/vaccines.html|website=cdc.gov|accessdate=17 April 2017}}</ref> || | ||
Revision as of 06:58, 17 April 2017
This is a timeline of malaria vaccine, attempting to describe its development.
Big picture
| Year/period | Key developments |
|---|
Full timeline
| Year/period | Type of event | Event | Location |
|---|---|---|---|
| 1984 | "GSK/WRAIR initiate collaboration"[1] | ||
| 1987 | "RTS,S is first created by combining the malaria CS protein and hepatitis B surface antigen"[1]
"The RTS,S malaria vaccine candidate is the most advanced in development globally. It was created in 1987 by scientists working at GlaxoSmithKline’s (GSK) laboratories."[1] || | ||
| 1995 | "First RTS,S clinical tests in humans begins in adults in US"[1] | ||
| 1997 | Key proof-of-concept (PoC) study shows 6 of 7 volunteers in challenge trial are 100% protected.[1] | ||
| 2009 | Trial | "GlaxoSmithKline Biologicals' (GSKBio) RTS,S" "A Phase III trial of the world’s most clinically advanced malaria vaccine candidate was launched in Kisumu, Kenya, in July 2009, under the auspices of the Kenya Medical Research Institute (KEMRI)/CDC Research and Public Health Collaboration."[2] | |
| 2011 | Trial | "The RTS,S vaccine was tested in Phase III trials in 11 different African countries. These trials have had some successes. The earliest results, released in October 2011, showed that in children aged 5-17 months, vaccination with RTS,S reduced the risk of clinical malaria and severe malaria by 56% and 47%, respectively.[17] However, in results released in November 2012, the vaccine was less effective in infants aged 6-12 weeks at first vaccination."[3] | |
| 2015 (July) | "The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced on July 24, 2015,that it has adopted a positive scientific opinion, under Article 58, for GSK’s malaria candidate vaccine Mosquirix TM, also known as RTS,S, in children aged 6 weeks to 17 months."[1] | ||
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Fact s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )" (PDF). malariavaccine.org. Retrieved 17 April 2017.
- ↑ "Malaria Vaccine". cdc.gov. Retrieved 17 April 2017.
- ↑ "Malaria and Malaria Vaccine Candidates". historyofvaccines.org. Retrieved 17 April 2017.
